The Number of Covered Individuals is Expected to Increase by More than 50 Million in 2016

OMAHA, Neb. (December 9, 2015) — Transgenomic, Inc. (NASDAQ: TBIO) today reported on the status of insurance reimbursement for its genomic cancer tests currently available for the detection of key mutations in lung cancer and colorectal cancer. At the end of 2015, more than 110 million people in the US had health insurance that covered Transgenomic’s cancer tests. They include plans that are part of UnitedHealthcare, Blue Cross/Blue Shield, Aetna, Humana, MultiPlan and the PHCS network, and other major insurers. The company also reported that it expects coverage to increase by more than 50 million lives in 2016, through revisions to existing contracts and expected signings of new contracts with additional insurers.

“We believe that our success in obtaining broad insurance coverage for our cancer tests reflects the fact that by design, our portfolio focuses on actionable genetic mutations that are included in current cancer guidelines and are of practical utility to patients and their oncologists, providing insight into which drugs might be most appropriate for the patient at that point in their treatment,” said Paul Kinnon, President and CEO of Transgenomic. “Since they are based on our unique ICE COLD-PCR™ technology, our tests also work exceptionally well with either blood or tissue samples, enabling their use with almost any cancer patient at all stages of the disease. We are pleased with the breadth of coverage to date and expect to increase insurer coverage in the new year, as we also work to educate doctors and patients about the advantages of our growing menu of cancer tests.”

Last month, Transgenomic announced the launch of its comprehensive Multiplexed ICE COLD-PCR Non-Small Cell Lung Cancer (NSCLC) Analysis panel that covers the key actionable mutations that are relevant to the targeted treatment of NSCLC, one of the most common types of cancer and the leading cause of cancer deaths in the US. It followed the earlier launch of tests for lung cancer and for detection of KRAS and NRAS mutations in colorectal cancer. Additional cancer tests are in development. Transgenomic’s cancer tests are available for clinical diagnostic use through the company’s CLIA laboratory.

For information on Transgenomic’s CLIA cancer tests, click here.

About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR™ technology and its unique genetic tests provided through its Patient Testing business. Transgenomic also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic’s filings with the Securities and Exchange Commission, including in Transgenomic’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 15, 2015. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

Contacts:

Media:
BLL Partners LLC
Barbara Lindheim
212-584-2276
blindheim@bllbiopartners.com

Investors:
Transgenomic Investor Relations
investor.relations@transgenomic.com